Randomised clinical trial: First-line infliximab biosimilar is cost-effective compared to conventional treatment in paediatric Crohn's disease.
Vuijk SA, Jongsma MME, Hoeven BM, Cozijnsen MA, van Pieterson M, de Meij TGJ, Norbruis OF, Groeneweg M, Wolters VM, van Wering H, Hummel T, Stapelbroek J, van der Feen C, van Rheenen PF, van Wijk MP, Teklenburg S, Rizopoulos D, Poley MJ, Escher JC, de Ridder L.
Vuijk SA, et al. Among authors: hummel t.
Aliment Pharmacol Ther. 2024 Apr 21. doi: 10.1111/apt.18000. Online ahead of print.
Aliment Pharmacol Ther. 2024.
PMID: 38644588